BioSpace News Archive

Alvotech Holdings S.A. has today announced the resolution of all intellectual property disputes with AbbVie in Europe and selected markets outside of Europe, related to its AVT02 biosimilar candidate.

ULTOMIRIS ® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks.

STAAR Surgical Company today announced the first implants of the EVO Visian® Implantable Collamer® lens (EVO ICL) in the U.S.

Evaxion Biotech A/S announced today that it will host a key opinion leader (KOL) webinar with a focus on personalized cancer immunotherapies and melanoma treatment options on Tuesday, April 12, 2022 at 12:30 pm ET.

OpGen, Inc. announced that its subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance, is expanding its strategic collaboration with Sandoz, aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance, and to that end has extended its collaboration agreement until January 31, 2025.

Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on April 1, 2022, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 23 new employees under Rule 5635 of the NASDAQ Listing Rules.

Akoya Biosciences, Inc., The Spatial Biology Company®, announced that two important milestones on advancing the speed and scale of its spatial phenotyping solutions, will be presented during the American Association for Cancer Research 2022 Annual Meeting in New Orleans, April 8 to 13.

Merus N.V. announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 at 10:15-10:55 a.m. ET.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the enrollment of the last subject in its ARRECTOR pivotal Phase 3 trial of topical roflumilast foam in adolescents and adults with scalp and body psoriasis.

Direct Biologics announces topline results from its first-in-human, multicenter, Phase II double-blind, placebo-controlled, randomized clinical trial, EXIT COVID-19,